FDA approves Leo Pharma's tralokinumab after rejection 8 months ago

Eight months after Leo Pharma's atopic eczema treatment, tralokinumab, was rejected in the US, the FDA gives the Danish firm's drug the thumbs-up. Leo Pharma can now market and sell the drug in the US, which could double the company's size, says Leo Pharma executive Becki Morison.
Leo Pharma is turning a page with the FDA's historic approval of tralokinumab as a treatment of atopic eczema, says a Leo Pharma executive | Photo: Leo Pharma / PR
Leo Pharma is turning a page with the FDA's historic approval of tralokinumab as a treatment of atopic eczema, says a Leo Pharma executive | Photo: Leo Pharma / PR
by ULRICH QUISTGAARD, translated by daniel pedersen

The US Food and Drug Administration (FDA) approves of Leo Pharma's biologic drug, tralokinumab, against atopic eczema in adults, Leo Pharma announce in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading